Patents Assigned to Allergan, Inc.
  • Patent number: 10758470
    Abstract: Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 1, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Elizabeta Pavlovic, Monica A. Serban, Xiaojie Yu, Nicholas J. Manesis
  • Patent number: 10752678
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 25, 2020
    Assignees: ALLERGAN, INC., XENCOR, INC.
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • Patent number: 10744227
    Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: August 18, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Xiaojie Yu, Darin J. Messina, Elizabeta Pavlovic, Cunqi Cui, Kate M. Smither
  • Patent number: 10736936
    Abstract: Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 11, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Michael E. Stern, David Power
  • Patent number: 10729751
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 4, 2020
    Assignee: Allergan, Inc.
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • Patent number: 10709545
    Abstract: A device can be used for both tissue expansion within a body of a patient as well as a permanently implanted prosthesis. Such a device can include an expandable elastomeric matrix and granules of a solute embedded within the matrix. The matrix can define boundaries of a plurality of chambers within the matrix. The device, when implanted within the body of the patient, can be exposed to fluid within the patient to create an osmotic gradient across a boundary of the device. Based on the gradient, fluid permeates the elastomer and gradually expands the chambers. The rate of expansion can be programmed to allow the body to naturally adapt to the volume, which increases until achieving a target volume in an expanded state.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: July 14, 2020
    Assignee: Allergan, Inc.
    Inventors: David J. Schuessler, Steven A. Schultz
  • Patent number: 10702539
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: July 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Patent number: 10702515
    Abstract: Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: July 7, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Charles R. Engles, Bryan Fuller, Brian Keith Pilcher
  • Patent number: 10703806
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: July 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Dianne Hodges, Kei Rogers Aoki
  • Patent number: 10682361
    Abstract: The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: June 16, 2020
    Assignee: Allergan, Inc.
    Inventors: Scott Whitcup, David Woodward, Patrick Hughes
  • Patent number: 10675144
    Abstract: A soft prosthetic implant shell, such as a silicone breast implant shell, that has discrete fixation surfaces thereon for tissue adhesion. The fixation surfaces may be provided on the posterior face of the shell, as well as either on the periphery or at discrete areas on the anterior face. Band-shaped fixation surfaces may be provided on the anterior face of the shell to generally match the angle of pectoralis major or pectoralis minor muscle groups. The fixation surfaces may be roughened areas of the shell, or may be separate elements adhered to the shell.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 9, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Dennis Van Epps, Thomas E. Powell
  • Patent number: 10668081
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: June 2, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Patent number: 10669265
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: June 2, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Patent number: 10661022
    Abstract: A substance delivery device that includes a hypodermic needle with a tube for receiving and containing a volume of a substance. The substance delivery device includes a rod, a portion of which is of a size and shape to fit within the tube of the hypodermic needle. The rod can be displaced into and within the tube to contact and apply a force to a volume of substance contained within the tube to cause, at least in part, the volume of substance to be discharged out of the tube. The substance delivery device includes a rod displacement mechanism that applies a force to the rod to cause the rod to be displaced into and within the tube. The substance delivery device also includes a needle retraction mechanism that is configured to apply a force to the hypodermic needle to cause the hypodermic needle to retract from within a patient.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: May 26, 2020
    Assignee: Allergan, Inc.
    Inventors: Kenneth N. Horne, Brian Domecus
  • Patent number: 10653621
    Abstract: Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 19, 2020
    Assignee: Allergan, Inc.
    Inventors: Cindy W. Wu, Michael R. Robinson, James A. Burke, Patrick M. Hughes
  • Patent number: 10639252
    Abstract: The present invention provides a skin peel composition including a plurality of substances, such as lactic acid, salicylic acid, and resorcinol and, additionally a post-inflammatory hyper pigmentation reducing substance such as a retinol (vitamin A) or retinol derivative. Skin is first prepared using an alcohol preparation followed by a combinations of acids and, lastly, a retinol or retinol derivatives. Other agents such as ascorbic acid (vitamin C) and vitamin E can be added as needed. Application of the skin peel composition may be either topically in the form of a cream or gel, and may further be injected subcutaneously into the skin to achieve deeper penetration of the composition within the skin layers of the area to be treated.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: May 5, 2020
    Assignee: Allergan, Inc.
    Inventors: Lora Colvan, Rahul Mehta, Sujatha Sonti
  • Patent number: 10633373
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 28, 2020
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Patent number: 10624997
    Abstract: The present specification discloses porogen compositions comprising a core material and shell material, methods of making such porogen compositions, methods of forming such porous materials using such porogen compositions, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: April 21, 2020
    Assignee: Allergan, Inc.
    Inventors: Futian Liu, Nicholas J. Manesis, Xiaojie Yu, Athene W. Chan
  • Patent number: 10619146
    Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: April 14, 2020
    Assignees: Ipsen Bioinnovation Limited, Allergan Inc.
    Inventors: Keith Foster, John Chaddock, Charles Penn, Kei Roger Aoki, Joseph Francis, Lance Steward
  • Patent number: 10617657
    Abstract: Devices and methods are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: April 14, 2020
    Assignee: Allergan, Inc.
    Inventors: Julie Himes, Dennis Giesing, Cheryl Larrivee-Elkins, Michael J. Cima, Purnanand Sarma, Paul Goldenheim